How do you pay?

How to pay the least

Ask for the cash price

Alvaiz

We didn’t find one.

  1. Ask your pharmacy for Alvaiz’s cash price, and one or two other pharmacies too.
  2. Alvaiz’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameAlvaiz
Authorized genericeltrombopag
Regular genericeltrombopag
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Alvaiz?
The original
–
–

Brand nameThe maker’s card

Teva’s ALVAIZ Savings Program (Savings Card)

Savings card from Teva Pharmaceuticals

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Print the card (PDF) 

Or call 1-844-248-7949. See the offer on alvaiz.com

In the maker’s words

“Patients may pay as little as $0 out of pocket for Teva’s ALVAIZ.”

From the maker’s offer on alvaiz.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Alvaiz itself, from the same company, sold without the brand name, and usually for less. For now Alvaiz is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ALVAIZ is a thrombopoietin receptor agonist indicated:

  • for the treatment of thrombocytopenia in adult and pediatric patients 6 years and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ALVAIZ should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
  • for the treatment of thrombocytopenia in adult patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. ALVAIZ should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy.
  • for the treatment of adult patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Limitations of Use:

  • ALVAIZ is not indicated for the treatment of patients with myelodysplastic syndrome (MDS).
  • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection.

Source: the FDA label for Alvaiz (Teva Pharmaceuticals, Inc.), January 1, 2026. Full label on DailyMed 

Good to know